We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Factors Promoting Increased Rate and Success of Pregnancy in the Thalassemia Population in Toronto

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00327639
Recruitment Status : Unknown
Verified July 2005 by University Health Network, Toronto.
Recruitment status was:  Recruiting
First Posted : May 18, 2006
Last Update Posted : May 18, 2006
Information provided by:
University Health Network, Toronto

Brief Summary:
Treatment of patients with beta thalassemia in North America has altered dramatically during the past 40 years, with improvements in transfusion therapy and introduction of iron chelation therapy. Thalassemia patients now enjoy an increased life expectancy to the fifth and sixth decades of life, with fertility and childbearing becoming important issues. Data regarding this important topic remain limited, without clear data regarding iron control including serial assessment of hepatic iron concentration, the need for assistance in becoming pregnant, and use of iron chelating agents during pregnancy. As the life expectancy increases and overall health improves in thalassemia, clear data on fertility, pregnancy complications, and the effect of pregnancy on maternal health in thalassemia patients are necessary since these will have a direct impact on patient care, quality of life, and patient expectations.

Condition or disease
Thalassemia Fertility Pregnancy

Layout table for study information
Study Type : Observational
Enrollment : 50 participants
Observational Model: Defined Population
Time Perspective: Other
Official Title: Factors Promoting Increased Rate and Success of Pregnancy in the Thalassemia Population in Toronto
Study Start Date : July 2005

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Thalassemia, thalassemia intermedia or E-thalassemia patients in Toronto
  • Subject has attempted conception

Exclusion Criteria:

  • Subject has any other form of blood disease
  • Subject has not attempted conception

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00327639

Layout table for location contacts
Contact: Anthony Apostoli, B.Sc. 416-340-4800 ext 6069 Anthony.Apostoli@uhn.on.ca

Layout table for location information
Canada, Ontario
University Health Network, Toronto General Hospital Recruiting
Toronto, Ontario, Canada, M5G 2C4
Contact: Valerie M Joseph    416-340-4800 ext 6507    Valerie.Joseph@uhn.on.ca   
Sponsors and Collaborators
University Health Network, Toronto
Layout table for investigator information
Principal Investigator: Nancy F Olivieri, MD University Health Network, Toronto General Hospital
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00327639    
Other Study ID Numbers: 00000
First Posted: May 18, 2006    Key Record Dates
Last Update Posted: May 18, 2006
Last Verified: July 2005
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn